Table 1 Baseline characteristics of different antithrombotic treatment groups with a total of 671 patients included between January 2016 and October 2019 at ICUs of 12 clinical sites: (1) intravenous unfractionated heparin (iUFH, prophylactic dosage), (2) iUFH (therapeutic dosage), (3) antiplatelet therapy (aspirin (100 mg/day) and/or P2Y12 receptor inhibitor, i.e. clopidogrel (75 mg/day), prasugrel (10 mg/day) or ticagrelor (90 mg twice daily)) with iUFH (prophylactic or therapeutic dosage) except for triple therapy and (4) triple therapy (DAPT including aspirin (100 mg/day) and a P2Y12 receptor inhibitor with iUFH in therapeutic dosage)
From: Percutaneous dilatational tracheotomy in high-risk ICU patients
Treatment group | (I) Heparin (prophylactic dosage) (n = 101) | (II) Heparin (therapeutic dosage) (n = 131) | (III) Aspirin and/or P2Y12 receptor inhibitor with Heparin (prophylactic or therapeutic dosage) except for triple therapy (n = 290) | (IV) DAPT with heparin (therapeutic dosage) (triple therapy) (n = 149) | Overall (n = 671) |
|---|---|---|---|---|---|
Age [years] mean ± SD | 55 ± 16 | 64 ± 13 | 66 ± 12 | 70 ± 12 | 65 ± 14 |
Gender [male] n (%) | 56 (55) | 80 (61) | 208 (72) | 99 (66) | 444 (66) |
Body mass index [kg/m2] mean ± SD | 26.02 ± 5.67 | 27.87 ± + 5.39 | 27.16 ± + 5.27 | 26.99 ± 4.68 | 27.08 ± 5.25 |
Reason for hospitalization | |||||
Acute respiratory failure (ARDS, COPD, pneumonia) n (%) | 38 (38) | 32 (24) | 43 (15) | 6 (4) | 119 (18) |
Sepsis n (%) | 12 (12) | 11 (8) | 9 (3) | 7 (5) | 39 (6) |
Acute myocardial infarciation n (%) | 0 (0) | 0 (0) | 78 (27) | 77 (52) | 155 (23) |
Shock (cardiogenic/septic/ hemorrhagic) n (%) | 28 (28) | 34 (26) | 48 (17) | 23 (15) | 133 (20) |
Others n (%) | 23 (23) | 54 (41) | 112 (39) | 36 (24) | 225 (34) |
Hypertension n (%) | 49 (49) | 78 (60) | 212 (73) | 116 (78) | 455 (68) |
Diabetes mellitus n (%) | 15 (15) | 38 (29) | 89 (31) | 55 (37) | 197 (29) |
Current smoker n (%) | 19 (19) | 34 (26) | 101 (35) | 42 (28) | 196 (29) |
Chronic kidney disease n (%) | 24 (24) | 54 (41) | 90 (31) | 50 (34) | 219 (33) |
Previous stroke n (%) | 5 (5) | 14 (11) | 42 (14) | 21 (14) | 82 (12) |
Atrial fibrillation n (%) | 8 (8) | 90 (69) | 107 (37) | 105 (70) | 310 (46) |
Aspirin n (%) | 0 | 0 | 266 (92) | 149 (100) | 415 (62%) |
P2Y12 inhibitor n (%) | 0 | 0 | 138 (48) | 149 (100) | 287 (43%) |
Creatinine [mg/dl] mean ± SD | 1.38 ± 0.87 | 1.63 ± 0.95 | 1.60 ± 0.94 | 1.52 ± 0.85 | 1.57 ± 0.95 |
Hemoglobin [g/dl] mean ± SD | 9.26 ± 1.55 | 9.28 ± 1.75 | 9.28 ± 1.46 | 9.34 ± 1.33 | 9.29 ± 1.51 |
Platelet count [G/l] mean ± SD | 216 ± 150 | 222 ± 131 | 212 ± 131 | 249 ± 130 | 223 ± 134 |
INR mean ± SD | 1.21 ± 0.42 | 1.23 ± 0.33 | 1.17 ± 0.30 | 1.24 ± 0.25 | 1.20 ± 0.32 |
aPTT [s] mean ± SD | 37.99 ± 15.68 | 48.65 ± 22.96 | 39.10 ± 14.15 | 47.66 ± 16.82 | 42.68 ± 17.58 |